Causes of drug resistance and glioblastoma relapses
Glioblastoma multiform^ is one of the most aggressive malignancies, wich standard of treatment not changed over the past decade, and the average life expectancy from diagnosis to death does not exceed two years in the most optimistic trials. The review examines the features of the glioblastoma micro...
Saved in:
| Main Authors: | A. A. Mitrofanov, D. R. Naskhletashvili, V. A. Aleshin, D. M. Belov, A. Kh. Bekyashev, V. B. Karakhan, N. V. Sevyan, E. V. Prozorenko, K. E. Roshchina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-04-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/615 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01) -
SURGICAL TACTICS REGARDING CEREBRAL METASTASES WITH HEMORRHAGES
by: E. V. Prozorenko, et al.
Published: (2015-04-01) -
Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment
by: G. P. Guens, et al.
Published: (2021-11-01) -
Structural alterations of the EGFR gene in glioblastoma samples as a prognostic factor and molecular target for therapy
by: V. O. Varachev, et al.
Published: (2024-10-01) -
Re-irradiation combined with bevacizumab in the treatment of glioblastoma recurrence
by: S. V. Belokon, et al.
Published: (2024-03-01)